Trials / Completed
CompletedNCT00895037
Study Evaluating Pharmacovigilance Of Refacto AF
Pharmacovigilance Evaluation Of Refacto Af (Registered) In Germany And Austria
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 101 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.
Detailed description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ReFacto AF (Moroctocog alfa) | Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively |
Timeline
- Start date
- 2009-07-17
- Primary completion
- 2016-10-19
- Completion
- 2016-10-19
- First posted
- 2009-05-07
- Last updated
- 2018-07-17
- Results posted
- 2018-07-17
Locations
24 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00895037. Inclusion in this directory is not an endorsement.